This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Lake Street Sticks to Its Buy Rating for Achieve Life Sciences (ACHV)
Lake Street analyst Mark Smith maintained a Buy rating on Achieve Life Sciences today and set a price target of $11.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Smith is a 4-star analyst with an average return of 6.7% and a 44.29% success rate. Smith covers the Consumer Cyclical sector, focusing on stocks such as Clarus, Lakeland Industries, and Red Robin Gourmet.
Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $13.20.
Based on Achieve Life Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $14.66 million. In comparison, last year the company had a GAAP net loss of $12.36 million
Read More on ACHV:
Disclaimer & DisclosureReport an Issue
- Achieve Life Sciences Charts Delayed Path to Launch
- Achieve Life Sciences files prospectus for resale of shares by holders
- Achieve Life Sciences Adds Director Amid Board Transitions
- Achieve Life Sciences reports Q1 EPS (19c), consensus (30c)
- Options Volatility and Implied Earnings Moves Today, May 12, 2026
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
